Camlin Fine Sciences · NSE: CAMLINFINE · BSE: 532834

Q3 FY25 results · Oct–Dec 2024

Camlin Fine Sciences reported revenue from operations of ₹433.49 crore (up 12.3% from Q3 FY24) and net loss of ₹7.47 crore for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY25	Q3 FY24	YoY	Q2 FY25	QoQ
Revenue from operations	433.49	385.89	+12.3%	422.97	+2.5%
Other income	1.34	1.66	−19.7%	12.10	−89.0%
Total income	434.83	387.55	+12.2%	435.07	−0.1%
Profit before share of associates & JVs and tax	1.52	(9.73)	Turned profit	(142.81)	Turned profit
Share of profit/(loss) of associates & JVs	(1.85)	0.00		0.51
Net profit for the period	(7.47)	(14.28)	Loss narrowed	(116.11)	Loss narrowed
Attributable to shareholders of the company	(4.14)	(11.79)	Loss narrowed	(100.23)	Loss narrowed
EPS, basic (₹)	(0.24)	(0.71)	Loss narrowed	(5.98)	Loss narrowed
Net margin (%)	-1.7	-3.7		-27.5

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY25	Q3 FY24	YoY	Q2 FY25	QoQ
Revenue from operations	205.07	185.61	+10.5%	226.91	−9.6%
Other income	6.82	2.13	+220.7%	3.08	+121.2%
Total income	211.89	187.73	+12.9%	229.99	−7.9%
Profit before tax	(7.19)	(17.69)	Loss narrowed	(110.54)	Loss narrowed
Net profit for the period	(5.63)	(11.64)	Loss narrowed	(72.62)	Loss narrowed
EPS, basic (₹)	(0.33)	(0.70)	Loss narrowed	(4.34)	Loss narrowed
Net margin (%)	-2.7	-6.3		-32.0

Consolidated

Filed with BSE: 14 Feb 2025, 16:24 IST
Board meeting: 14 Feb 2025
Period: 01 Oct 2024 to 31 Dec 2024
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 14 Feb 2025, 16:24 IST
Board meeting: 14 Feb 2025
Period: 01 Oct 2024 to 31 Dec 2024
Review status: Unaudited
Source: XBRL filing on BSE